Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SNSE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSensei Biotherapeutics stockholders approve change of control and 24x share authorization increase
Filed June 10, 2026 · Period ending June 10, 2026 · ~1 min read
Key Changes
-
high
Stockholders approved conversion of Series B Preferred Stock that will trigger a change of control under Nasdaq rules, meaning existing common shareholders will be significantly diluted and control shifts to preferred holders.
Item 5.07: Annual Meeting verify on EDGAR → -
high
Authorized common stock increased from 12.5 million to 300 million shares (24x expansion), providing capacity for the preferred conversion and future capital raises but creating massive dilution potential.
Item 5.03: Charter Amendment verify on EDGAR → -
high
New 2026 Equity Incentive Plan approved with 2.7 million shares initially reserved, plus automatic annual increases of 5% of outstanding shares each January through 2036 for employee compensation.
Item 5.02: Equity Plans verify on EDGAR → -
medium
Employee Stock Purchase Plan approved with 267,198 shares reserved, automatically increasing annually by lesser of 1% of outstanding shares or twice initial reserve through 2036.
Item 5.02: ESPP verify on EDGAR → -
low
Bob Holmen and Kristian Humer elected as directors until 2029; Deloitte & Touche ratified as auditor for 2026 with overwhelming support.
Item 5.07: Routine Matters verify on EDGAR →
Summary
Sensei Biotherapeutics stockholders approved a transformative restructuring at their June 10 annual meeting.
The most significant action was approving conversion of Series B Preferred Stock into common shares, which will trigger a change of control under Nasdaq rules—meaning existing common stockholders will see their ownership stakes dramatically diluted and control of the company will shift to the preferred holders.
To accommodate this conversion, stockholders also approved a 24-fold increase in authorized shares from 12.5 million to 300 million, creating enormous capacity for future dilution. The company also established new equity compensation programs that will further dilute shareholders over the next decade. The 2026 Equity Incentive Plan starts with 2.7 million shares and automatically grows by 5% of outstanding shares annually through 2036, while the Employee Stock Purchase Plan adds another 267,000 shares with similar automatic increases. Retail investors should immediately assess their position: the preferred conversion represents a fundamental change in who controls the company. Watch for the actual conversion date and resulting ownership percentages in upcoming filings to understand the full dilution impact on your stake.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Sensei Biotherapeutics held annual meeting; stockholders approved preferred stock conversion triggering change of control and 24x increase in authorized shares.
Added in current filing · verify on EDGAR →
Approval of the issuance of shares of the Company’s common stock upon conversion of the Company’s Series B Non-Voting Convertible Preferred Stock, which will (a) represent more than 20% of the shares of common stock outstanding and (b) result in the change of control of the Company pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively
Stockholders approved the conversion of Series B Non-Voting Convertible Preferred Stock into common stock, which will result in a change of control of the company under Nasdaq rules. This means existing common stockholders will be significantly diluted and control of the company will shift to the preferred stockholders upon conversion. The proposal passed with 747,293 votes for versus 3,397 against.
Added in current filing · verify on EDGAR →
Proposal No. 5: Approval of the 2026 Plan. The votes were cast as follows: Votes For | Votes Against | Abstained | 484,662 | 266,010 | 14,850
Stockholders approved the 2026 Plan (likely an equity incentive plan) and the 2026 ESPP (employee stock purchase plan), though both proposals faced more opposition than other items with roughly 35% of votes cast against. These plans will allow the company to grant stock-based compensation to employees and directors, creating additional dilution for existing stockholders.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
Name | Votes For | Votes Withheld | Bob Holmen | 741,993 | 23,529 | Kristian Humer | 741,275 | 24,247
Bob Holmen and Kristian Humer were elected to serve as directors until the 2029 annual meeting. Both received over 740,000 votes for with minimal opposition. This is a routine governance matter with no apparent controversy.
Added in current filing · verify on EDGAR →
Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: Votes For | Votes Against | Abstained | 1,055,703 | 3,879 | 17,592
Stockholders ratified Deloitte & Touche LLP as the company's auditor for 2026 with overwhelming support. This is a routine annual matter with no indication of auditor issues or concerns.
Event · Item 9.01 — Financial Statements and Exhibits
Sensei Biotherapeutics filed exhibits for a certificate of incorporation amendment, new equity incentive plan, and employee stock purchase plan.
Added in current filing · verify on EDGAR →
Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Company, effective June 10, 2026
The company amended its certificate of incorporation effective June 10, 2026. The 8-K does not disclose the substance of the amendment, only that it occurred and the exhibit is attached.
Added in current filing · verify on EDGAR →
2026 Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Grant Agreement thereunder
The company adopted a new 2026 Equity Incentive Plan with associated grant forms for stock options and restricted stock units. This plan will govern future equity compensation to employees and other service providers, potentially diluting existing shareholders.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
2026 Employee Stock Purchase Plan
The company adopted a 2026 Employee Stock Purchase Plan, which typically allows employees to purchase company stock at a discount through payroll deductions. This may result in additional share issuance and dilution.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify